Call it a bifurcated intellect or maybe a good old case of schizophrenia, but the business media's headline coverage of Eli Lilly's ( LLY) earnings report yesterday was enough to leave the savvy investor with bad case of motion sickness.Headlines were all over the place, lurching this way and that. Dow Jones went with dour -- " Eli Lilly Posts Loss on Zyprexa Probe Costs" -- while Forbes ran with celebratory -- " Lilly Delivers On Drug Front: Lilly Surprises With Solid Earnings, Raised Guidance." The Associated Press split the difference: " Eli Lilly posts 3Q loss but eyes more growth." Reuters played its part and ran the gamut all by itself. First, a little bit of dour: " Lilly posts loss on charges for Zyprexa probes." And later in the day, something more celebratory: " Bristol, Lilly top profit targets on strong sales." Come to think of it, the Associated Press switched gears later in the day, too. With its first headline, it panted both feet firmly up in the air, but later in the day it took a more definitive -- and positive -- stance: " Lilly, Bristol-Myers post solid 3Q sales growth."